To amend title XXVII of the Public Health Service Act to establish civil liability for health insurance issuers with high levels of claims denials.
Summary
HR8442 (Patient Refunds for Bad Denials Act) is an early-stage bill with one sponsor and one cosponsor, referred to committee on April 22, 2026. It proposes civil penalties for health insurers with claims denial rates at or above 25%, but faces a long legislative path. Major health insurers ($HUM, $CI, $CVS) have rallied 9-38% over 30 days, and this bill presents no immediate stock-moving catalyst given its procedural stage.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR8442 is a procedural early-stage bill with no near-term market impact.
- 2.The bill authorizes no spending—it creates a penalty framework with no funding mechanism.
- 3.Real market data shows health insurers rallying significantly post-introduction, indicating the market is not pricing in this risk.
- 4.Legislative path requires passage through both chambers and presidential signature—unlikely in current form given limited support.
Market Implications
No immediate market implications given the bill's procedural stage. The 9-38% rally in major health insurers over the past 30 days reflects sector fundamentals, not legislative overhang. $HUM at $238.85, $CI at $291.50, and $CVS at $83.11 all trade near their recent highs, with no selling pressure observed around the April 22 introduction date. Investors should monitor committee scheduling for any markup activity, which would be the first meaningful signal of legislative momentum.
Full Analysis
HR8442 was introduced on April 22, 2026 by Rep. Craig (D-MN) and referred to the House Committee on Energy and Commerce. The bill, with only one cosponsor and no further action history, is at the earliest legislative stage. It proposes a civil monetary penalty framework for health insurance issuers whose claims denial percentage reaches 25% or greater, with enforcement via HHS audits. However, this bill does not authorize or appropriate any funding—it creates a regulatory penalty structure. Actual market impact requires the bill to advance through subcommittee markup, full committee, House floor, Senate, and presidential action—a multi-year process with high attrition probability. Real market data shows $HUM up 37.75% over 30 days, $CI up 9.28%, and $CVS up 15.72%. These rallies are driven by factors unrelated to this bill (e.g., earnings, broader sector rotation), not legislative risk. $HUM's close on the bill's introduction date was $217.40, and it rose 9.9% over the following week to $238.85—directly contradicting any negative market reaction to the news.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
DELL FEDERAL SYSTEMS L.P: $1.0B Department of Veterans Affairs Contract
OPTUM PUBLIC SECTOR SOLUTIONS, INC.: $641M Department of Veterans Affairs Contract
OPTUM PUBLIC SECTOR SOLUTIONS, INC.: $773M Department of Veterans Affairs Contract
OPTUM PUBLIC SECTOR SOLUTIONS, INC.: $598M Department of Veterans Affairs Contract
Executive Order: Promoting Efficiency, Accountability, and Performance in Federal Contracting
Executive Order: Accelerating Medical Treatments for Serious Mental Illness
ADVANCED TECHNOLOGY INTERNATIONAL: $304M Department of Health and Human Services Contract
Executive Order: Realigning United States Core Childhood Vaccine Recommendations with Best Practices from Peer, Developed Countries
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Implementing Schedule Policy/Career in the Excepted Service
This executive order expands the Schedule Policy/Career excepted service category, transferring certain federal positions from competitive service to at-will employment to facilitate removal for poor performance or misconduct. It directs agency heads to petition for reclassification of policy-influencing roles, mandates performance bonus pools for these employees, and amends civil service rules to exempt them from standard adverse action procedures.
Realigning United States Core Childhood Vaccine Recommendations with Best Practices from Peer, Developed Countries
This executive order directs the CDC and ACIP to review and potentially update the U.S. childhood vaccine schedule to align with recommendations from peer developed countries, which recommend fewer vaccines. It maintains insurance coverage for all currently available vaccines without cost sharing and emphasizes protecting religious liberty and parental authority.
Promoting Efficiency, Accountability, and Performance in Federal Contracting
This executive order mandates that federal agencies default to using fixed-price contracts for procurement, shifting away from cost-reimbursement models. It requires written justification and senior-level approval for any non-fixed-price contract over certain dollar thresholds (e.g., $10M for most agencies, $100M for the Department of War), and directs agencies to review and renegotiate their 10 largest non-fixed-price contracts within 90 days. The order also tasks OMB with implementation guidance and the Federal Acquisition Regulatory Council with proposing regulatory amendments within 120 days.